We believe that life sciences job seekers should deal with industry experts when seeking their next role in the life sciences field.
Hays Life Sciences has over ten years of experience in recruiting directly for the life sciences industry and count all of the top 20 global pharmaceutical organisations as clients.
By engaging with our specialists, job seekers gain instant access to a network of leading Canadian employers who rely on us to keep them informed of the best new talent as soon as it becomes available.
Vancouver or Calgary
Commensurate with experience
West Greater Toronto Area
Commensurate with experience
Greater Toronto Area
Generous executive compensation package
$100,000 - $110,000
Speak to a recruitment expert at your local Hays office.
Expert advice on job searching, applications and interview techniques.
Join our Life Sciences group for the latest industry insights.Join our group
Oncology drug development series - Spotlight on the USA - 28/05/13
Oncology drug development continues to see a high level of activity and funding across the US, despite an uncertain regulatory environment.
Drugs off patent series: How Pfizer approached life post-Lipitor - 16/05/13
How do you hang on to your profits – and your employees – when your best-selling drug of all time comes off patent?
Drugs off patent series – GlaxoSmithKline’s Advair - 02/05/13
GlaxoSmithKline’s Advair Diskus is prescribed for chronic asthma and sufferers of chronic obstructive pulmonary disease (COPD) including chronic bronchitis and/or emphysema.
Spotlight on –Three person embryo - 26/04/13
Families at risk of incurable genetic diseases have so far played a lottery with both natural and artificial pregnancies that could result in a child inheriting these traits.
Viagra – drugs off patent series - part two - 19/04/13
Viagra (sildenafil citrate) is probably one of the most significant brand names that was coming out of patent in the USA and so it is not surprising that its manufacturer Pfizer has been fighting for a patent extension.
Blockbuster drugs patent expiry part one - 05/04/13
Viagra, Seroquel, Lipito… One of the biggest shake-ups to hit the large drug companies over the last few years is the sight of so many high profile – and highly profitable - drugs coming out of patent.
Oncology drug development - spotlight on UK - 02/04/13
Is science investment – and particularly investment in oncology research and development roles - the way to grow the UK economy and push through the recession?
Changing locations for clinical trials - part one - 28/03/13
Clinical trial locations are no longer restricted to a handful of key scientific bases in the UK, US and Europe.
The impact of oncology drug development - part one - 21/03/13
In the first of our occasional series, we look at how recent oncology drug advances have had an impact on global skills and recruitment trends.